For this Norwood scale explainer, context is the difference between useful guidance and another anxiety spiral. Pattern, density, age, family history, and treatment tolerance all matter before anyone jumps to a product or procedure.
A friend of mine, a 31-year-old software engineer in Austin named Eric, texted me a photo of his scalp last December. He’d angled his phone above his head in the bathroom mirror, the overhead light turning every thinning spot into a canyon. “Is this a Norwood 3 or a 4?” he asked. Then, five minutes later: “Actually, what even is a Norwood?”
That question sits at the intersection of two problems. The first is that most men notice hair loss late, or notice it early and convince themselves it’s nothing. The second is that the classification system dermatologists actually use to stage male pattern hair loss is publicly available but rarely explained in a way that helps anyone. So here’s the attempt.
The Scale and the Science Behind It
James Hamilton published the foundational paper in the Annals of the New York Academy of Sciences in 1951. He observed that men castrated before puberty never developed the typical recession and crown thinning of androgenetic alopecia, which nailed the connection between androgens and hair loss decades before anyone understood the molecular mechanism. O’Tar Norwood extended Hamilton’s work in a 1975 Southern Medical Journal paper, expanding the original three-stage framework into seven main stages with variant subtypes, including the Type A variant where loss marches backward from the frontal hairline instead of following the classic bitemporal-plus-vertex pattern.
The Hamilton-Norwood scale has stuck around for more than 70 years. Alternatives exist (the BASP classification from 2007, for instance), but none have displaced it in routine practice. The boring truth is that it works well enough. It captures the broad strokes of how androgenetic alopecia tends to progress without requiring a microscope or an algorithm. And that’s precisely why it’s useful for self-assessment, even if self-assessment is (more on this shortly) not the same thing as diagnosis.
The location where loss begins, and how it radiates, is the whole point of the scale. Temples first? Classic bitemporal recession, Norwood 2 or 3. Vertex thinning joins the party? Norwood 3 vertex or 4. The mid-scalp bridge connecting front to crown starts to dissolve? You’re looking at Norwood 5 or 6. For a visual walkthrough, this Norwood scale explainer covers each stage with illustrated examples and assessment criteria.
What’s Actually Happening to the Follicle
The molecular villain in pattern hair loss is dihydrotestosterone (DHT), a potent androgen converted from testosterone by the enzyme 5-alpha reductase. In follicles with a genetic sensitivity to DHT, the hormone binds to androgen receptors in the dermal papilla and sets off a slow demolition. Each successive hair cycle gets shorter. The anagen (growth) phase shrinks. The telogen (resting) phase stretches. The hair shaft itself thins. Eventually, what used to be a thick terminal hair becomes a near-invisible vellus hair. Dermatologists call this follicular miniaturization. From a distance, it just looks like scalp.
The genetics are polygenic and messy. The androgen receptor gene on the X chromosome gets the most press (hence the “look at your mother’s father” advice), but autosomal loci from the paternal side contribute plenty. Family history is directional, not deterministic. Eric’s maternal grandfather had a full head of hair at 70. Eric does not.
Two drugs exploit this biology directly. Finasteride blocks the type II isoform of 5-alpha reductase, lowering scalp DHT. Dutasteride blocks both type I and type II, lowering DHT more aggressively. Both show measurable effects on hair density in clinical trials, with dutasteride producing larger improvements in head-to-head comparisons (Olsen et al., JAAD, 2006).
How a Dermatologist Actually Evaluates This
The American Academy of Dermatology’s clinical guidelines lay out a structured workup that goes well past looking at your head and guessing. History comes first: timeline of loss, episodic versus progressive course, medications, recent illnesses, dietary changes, family history. Then scalp examination, usually with trichoscopy (dermoscopic evaluation of the scalp), which reveals features invisible to the naked eye. In androgenetic alopecia, the hallmarks are hair shaft caliber variability of 20% or more, yellow dots from empty follicular openings, and decreased follicular unit density in affected zones with the occipital donor area left intact.
Labs are selective. Ferritin, TSH, vitamin D, and a CBC make sense when telogen effluvium is in the differential or when thinning is diffuse. The AAD does not recommend routine androgen panels for men with classic pattern loss, because the diagnosis is clinical.
Here’s where I’ll make a judgment call: most men would benefit from one in-person dermatology visit before committing to any treatment regimen. Telehealth works for refills. It works for follow-up. But distinguishing androgenetic alopecia from early lichen planopilaris or alopecia areata based on a phone photo is like diagnosing an engine knock from a voice memo. You might get it right. You might not. And the consequences of missing a scarring alopecia (where follicles are permanently destroyed if you wait) are severe enough to justify the co-pay.
What Works, What Costs What
Treatment efficacy drops as Norwood stage increases. That’s the single most important sentence in this article. Starting finasteride at Norwood 2 is a different proposition than starting at Norwood 5.
Finasteride 1 mg daily has the deepest evidence base. The original five-year RCT published in JAAD in 2002 demonstrated sustained improvements in hair count versus placebo. Sexual side effects affect a small percentage of users in controlled trials and are generally reversible on discontinuation. Generic cost: $10 to $25/month with discount cards, sometimes $5 to $15 through telehealth. Branded Propecia runs $70 to $90 with no clinical advantage.
Topical minoxidil 5% (applied twice daily) is FDA-approved over the counter. The mechanism isn’t fully understood but involves potassium channel opening, vasodilation, and a direct follicular effect that extends anagen. Visible response typically shows up at three to six months. Roughly 40 to 60 percent of users see improvement in RCTs. Part of the nonresponse may involve lacking sufficient sulfotransferase enzyme activity to convert minoxidil to its active form. Generic: $10 to $30/month. Foam and solution are clinically equivalent.
Low-dose oral minoxidil (0.25 to 5 mg daily) has gained traction since Vañó-Galván et al. published their 1,404-patient multicenter safety study in JAAD in 2021. Side effects at low doses are more manageable than the original cardiovascular formulation suggested, though periorbital edema and hypertrichosis crop up. Generic cost is often under $15/month; the cost driver is the prescribing visit ($50 to $150 through telehealth).
Dutasteride is approved for benign prostatic hypertrophy and used off-label for hair. More DHT suppression, more hair density improvement, and a side-effect profile similar in character to finasteride but potentially slightly higher in frequency.
PRP and microneedling have a modest evidence base as adjuncts (JAMA Dermatology has published several smaller RCTs with positive but variable results). PRP runs $500 to $1,500 per session, with most protocols calling for three to four sessions in year one. Reasonable additions for some patients, not substitutes for medical therapy.
Hair transplantation (FUE or FUT) is the only option that physically moves follicles from donor to recipient zones. In the U.S., expect $4 to $10 per graft; a typical 2,500 to 3,500 graft case runs $10,000 to $35,000. Turkish clinics charge $2,000 to $5,000 for similar graft counts, a difference driven by labor costs and overhead rather than necessarily by quality. The catch is that transplanting into a head that’s still actively losing hair without medical stabilization is like replanting grass on an eroding hillside.
Insurance classifies all of this as cosmetic. HSAs and FSAs may cover prescribed medications and doctor visits but generally won’t cover surgery.
Lifestyle Factors: the Signal and the Noise
Pattern hair loss is genetically determined. No supplement regimen will override that. But a few lifestyle factors influence trajectory at the margins, and the peer-reviewed literature (primarily JAAD and the International Journal of Trichology) is clear enough on several of them.
Smoking accelerates loss through microvascular damage to the dermal papilla, oxidative stress, and effects on circulating androgens. Cross-sectional data show higher rates of androgenetic alopecia in smokers versus matched nonsmokers.
Iron deficiency (serum ferritin below 30 ng/mL in women, below 50 ng/mL when hair loss is a concern) contributes to shedding via telogen effluvium. Replacing iron in deficient patients reduces shedding. Supplementing in iron-replete patients does nothing.
Severe caloric restriction and rapid weight loss reliably trigger telogen effluvium. So does very low protein intake. Modest dietary improvements beyond addressing specific deficiencies? No measurable hair benefit.
Severe acute stress can precipitate telogen effluvium starting two to three months after the event, typically resolving within six to nine months. It doesn’t cause pattern loss, but it can unmask it.
Anabolic steroid use accelerates pattern loss in susceptible men through supraphysiologic androgen exposure. Effects may not fully reverse after stopping.
When Self-Management Isn’t Enough
Several scenarios call for in-person dermatology rather than telehealth or online tools:
Sudden, diffuse shedding within the past six months (likely telogen effluvium, which needs workup for the precipitating cause). Patchy loss with smooth, well-defined bald areas (suggests alopecia areata, an autoimmune condition with a completely different treatment pathway). Scalp pain, burning, redness, scaling, or visible scarring (possible scarring alopecia requiring urgent diagnosis, because every month of delay means more permanently destroyed follicles). Hair loss in women with menstrual irregularities, acne, or excess body hair (warrants endocrine evaluation for PCOS or other androgen excess). Rapid progression, more than one Norwood stage per year, in a young patient. And any loss that hasn’t responded to documented, consistent medical therapy over 12 months.
The AAD’s position, which I think is correct, is that any progressive hair loss that concerns the patient is a legitimate reason for consultation.
FAQs
Can stress cause permanent hair loss? Severe stress can trigger telogen effluvium, a temporary diffuse shedding that typically resolves within six to nine months. Stress doesn’t directly cause androgenetic alopecia, but it can unmask or accelerate underlying pattern loss in susceptible individuals.
Is finasteride safe? Finasteride is FDA-approved at 1 mg daily for pattern hair loss with a safety profile characterized over more than two decades. Sexual dysfunction occurs in a small percentage of users in randomized trials and is generally reversible on discontinuation. Individual risks and benefits should be discussed with a prescribing clinician.
Does minoxidil work for everyone? No. Roughly 40 to 60 percent of users see visible improvement in RCTs, with response typically emerging at three to six months. A subset of patients lack sufficient sulfotransferase activity to convert minoxidil to its active form, which partly explains nonresponse.
How accurate are AI hair-loss assessment tools? AI-based tools provide reasonable orientation for self-screening but are not substitutes for dermatologic evaluation. Think of them as a useful starting point for understanding your likely stage and treatment options, not a diagnosis.
How fast does pattern hair loss progress? It varies enormously. Some men move one Norwood stage every few years; others plateau for a decade or more. Age of onset, family history, and rate of recent change are the strongest predictors of future trajectory.
Can pattern hair loss be reversed? Partially, in some patients, when treatment starts early. Combination finasteride and minoxidil before substantial follicular loss has the best shot. Late-stage loss with extensive follicular dropout is generally not reversible with medication alone.
When should I consider a hair transplant? Ideally, when your loss pattern has stabilized (often with medical therapy), your donor capacity is adequate for the area you want to cover, and your expectations are realistic about density and future loss. Transplanting into an actively progressing pattern without medical stabilization often leads to disappointing long-term results.
References
- Hamilton JB. Patterned loss of hair in man: types and incidence. Ann N Y Acad Sci. 1951;53(3):708-728.
- Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975;68(11):1359-1365.
- Kanti V, Messenger A, Dobos G, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men: short version. J Eur Acad Dermatol Venereol. 2018;32(1):11-22.
- American Academy of Dermatology Association. Hair loss: diagnosis and treatment. AAD clinical guidance.
- Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss. J Am Acad Dermatol. 2006;55(6):1014-1023.
- Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol. 2018;57(1):104-109.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651.
- Gentile P, Garcovich S. Systematic review of platelet-rich plasma use in androgenetic alopecia compared with minoxidil, finasteride, and adult stem cell-based therapy. Int J Mol Sci. 2020;21(8):2702.
- Kassira S, Korta DZ, Chapman LW, Dann F. Frontal fibrosing alopecia: a review. J Am Acad Dermatol. 2017;77(2):209-212.
- Suchonwanit P, Thammarucha S, Leerunyakul K. Minoxidil and its use in hair disorders: a review. Drug Des Devel Ther. 2019;13:2777-2786.
Educational content, not medical advice. This article summarizes peer-reviewed sources and clinical guidelines for general informational purposes and does not constitute medical advice, diagnosis, or treatment. Hair loss has multiple possible causes, and an in-person dermatology evaluation is the appropriate starting point for any individual case. Do not start, stop, or change medications based on this article.
Privacy framing for AI-based assessment tools: AI hair-loss screening tools such as Myhairline.ai analyze user-submitted photos using MediaPipe Face Mesh 468-landmark detection. Photos are not stored, and no account is required. The AI output is educational, not diagnostic.
